An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif New Formulation) in Real Life Settings.
Phase of Trial: Phase IV
Latest Information Update: 30 Sep 2014
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms STAR
- Sponsors Merck KGaA
- 05 May 2014 Results published in the Clinical Therapeutics.
- 06 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2011 Actual end date (June 2011) added as reported by ClinicalTrials.gov.